Sugi Predict

Sugi Predict / Compounds / SCHEMBL1740885

SCHEMBL1740885

SCHEMBL1740885

CO[C@H]1O[C@H](C(O)C(=O)c2ccccc2C)[C@@H](F)[C@@]1(C)O

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.30
▸ SLC6A2 P23975 1/20 0.30
▸ SLC6A4 P31645 1/20 0.30
▸ SLC6A3 Q01959 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1740883 0.74 L3MBTL1 (0.38) —
SCHEMBL1738678 0.74 MEN1 (0.32) SLC6A2SLC6A4SLC6A3
SCHEMBL5707590 0.73 NPC1 (0.33) LMNASLC6A2SLC6A4SLC6A3
SCHEMBL1682170 0.72 HIF1A (0.33) LMNA
SCHEMBL1824334 0.70 ADRB2 (0.30) —
SCHEMBL5707571 0.69 P2RX7 (0.32) LMNASLC6A2SLC6A4SLC6A3
SCHEMBL5707632 0.69 P2RX7 (0.32) LMNASLC6A2SLC6A4SLC6A3
SCHEMBL4982728 0.69 P2RX7 (0.32) LMNASLC6A2SLC6A4SLC6A3
SCHEMBL5707724 0.68 NPC1 (0.31) —
SCHEMBL5707579 0.68 NPC1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140309412-A1 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE IONIS PHARMACEUTICALS, INC. 2014-10-16 — — US disclosed
US-8481712-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME CORP. (US) 2013-07-09 — — US disclosed
US-20120165515-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME LLC 2012-06-28 — — US disclosed
EP-2399588-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase Merck Sharp & Dohme Corp. (US) 2011-12-28 — — EP disclosed
US-7323453-B2 Methods of inhibiting orthopoxvirus replication with nucleoside compounds MERCK & CO., INC. (US) 2008-01-29 — — US disclosed
US-20070275912-A1 Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase MERCK SHARP & DOHME CORP. 2007-11-29 — — US disclosed
US-7202224-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK & CO., INC. (US) 2007-04-10 — — US disclosed
US-20060264390-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase IONIS PHARMACEUTICALS, INC. 2006-11-23 — — US disclosed
US-7125855-B2 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK & CO., INC. (US) 2006-10-24 — — US disclosed
EP-1707571-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase Merck & Co., Inc. (US) 2006-10-04 — — EP disclosed
US-20050164960-A1 Methods of inhibiting orthopoxvirus replication with nucleoside compounds MERCK SHARP & DOHME CORP. 2005-07-28 — — US disclosed
EP-1539188-A2 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE Merck & Co., Inc. (US) 2005-06-15 — — EP disclosed
US-6777395-B2 VIRICIDES MERCK & CO., INC. 2004-08-17 — — US disclosed
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase MERCK SHARP & DOHME LLC 2004-06-10 — — US disclosed
US-20040072788-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase BHAT BALKRISHEN (US) 2004-04-15 — — US disclosed
US-20040067901-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME LLC 2004-04-08 — — US disclosed
US-20040014108-A1 Oligonucleotides having modified nucleoside units ISIS PHARMACEUTICALS, INC. 2004-01-22 — — US disclosed
WO-2003100017-A2 OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS ISIS PHARMACEUTICALS, INC. (US) 2003-12-04 — — WO disclosed
US-20020147160-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase MERCK SHARP & DOHME LLC 2002-10-10 — — US disclosed
WO-2002057425-A2 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE MERCK & CO., INC. (US) 2002-07-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040067901-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT LMNA 3234/4885SLC6A2 1869/4885SLC6A4 2217/4885
US-20040014108-A1 Oligonucleotides having modified nucleoside units RNASEH1, RNASE1, RNASEL LMNA 1520/4885SLC6A2 4397/4885SLC6A4 3890/4885
US-20040110717-A1 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase NSUN2, NSUN3, POLRMT LMNA 3403/4885SLC6A2 1963/4885SLC6A4 2302/4885
US-20060264390-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT LMNA 3234/4885SLC6A2 1869/4885SLC6A4 2217/4885
US-20040072788-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT LMNA 3234/4885SLC6A2 1869/4885SLC6A4 2217/4885
US-20140309412-A1 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF RNA-DEPENDENT RNA VIRAL POLYMERASE NSUN2, NSUN3, POLRMT LMNA 3234/4885SLC6A2 1869/4885SLC6A4 2217/4885
US-20020147160-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT LMNA 3234/4885SLC6A2 1869/4885SLC6A4 2217/4885
US-20120165515-A1 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT LMNA 3234/4885SLC6A2 1869/4885SLC6A4 2217/4885
US-20070275912-A1 Nucleoside derivatives as inhibitors of rna-dependent RNA viral polymerase NSUN2, NSUN3, POLRMT LMNA 3234/4885SLC6A2 1869/4885SLC6A4 2217/4885
US-20050164960-A1 Methods of inhibiting orthopoxvirus replication with nucleoside compounds ITPA, PNP, NUDT1 LMNA 3111/4885SLC6A2 1445/4885SLC6A4 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.